Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ASIT-biotech logo — company profile

ASIT-biotech

Founded 1997 Belgium Belgium 1 employees Post-IPO Debt Total: $12.00M Biotechnology, Health Care

General Information

Company Name ASIT-biotech
Founded Year 1997
Location Belgium Belgium
Founders / Decision Makers
Team member
Employees 1
Industries Biotechnology, Health Care
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with ASIT-biotech. To contact ASIT-biotech, visit asitbiotech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ASIT-biotech compare?

A PDF of ASIT-biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ASIT-biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ASIT-biotech

ASIT biotech, a Belgian clinical stage biopharmaceutical company founded in 1997, is dedicated to developing and commercializing innovative immunotherapy products for allergy treatment. The company's unique ASIT+TM technology platform sets it apart as the sole developer of AIT product candidates incorporating a distinctive blend of highly purified natural allergen fragments optimized for efficacy. This breakthrough technology promises shorter treatment durations, potentially enhancing patient compliance and real-world effectiveness. With its headquarters in Belgium, ASIT biotech recently received a €12.00MPost-IPO Debt investment in July 2018. This injection of funds highlights growing investor confidence in the company's promising approach to allergy therapeutics within the biotechnology and healthcare industries.

Business keywords: ASIT biotech, biopharmaceutical company, immunotherapy, allergies, ASIT+TM technology platform, AIT product candidates, allergen fragments, patient compliance, real-life effectiveness, clinical stage, Belgian company

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt €12.00M -
11 Jul 2018

ASIT-biotech Alternatives & Competitors

View All Alternatives
ASIT-biotech vs
CG Oncology
CG Oncology United States

Attacking Bladder Cancer for a Better Tomorrow

Series F
121 employees
Biotechnology, Health Care
ASIT-biotech vs
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. United States

Innovative pediatric immunotherapies for Real-life Possibilities

Post-IPO Equity
59 employees
Biotechnology, Health Care
ASIT-biotech vs
DBV Technologies
DBV Technologies France

On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin...

Post-IPO Equity
187 employees
Biopharma, Biotechnology
View all alternatives

FAQ About ASIT-biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+TM technology platform, ASIT biotech is currently the only develo...
ASIT-biotech was founded in 1997.
ASIT-biotech is headquartered in Belgium.
ASIT-biotech operates in Biotechnology and Health Care. Its work centres on ASIT biotech, biopharmaceutical company, immunotherapy and allergies.
ASIT-biotech has approximately 1 employees.
ASIT-biotech has completed 1 funding round, raising a total of $12.00M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to ASIT-biotech include CG Oncology, Y-mAbs Therapeutics, Inc., DBV Technologies, Applied Therapeutics, Inc., SFA Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ASIT-biotech and CG Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ASIT-biotech, https://bouncewatch.com/company/asit-biotech, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout